Kala Bio signs LOI to distribute Virotek ophthalmic genetic tests
Kala Bio has signed a letter of intent with Virotek to become the exclusive U.S. distributor of Virotek's ophthalmology genetic testing and screening programme, a deal the two companies say could generate near-term revenue for the NASDAQ-listed clinical-stage biopharmaceutical firm.
Under the proposed arrangement, Kala would market and distribute the programme to eye care practices, telehealth platforms and other channels, while Virotek retains responsibility for its CLIA-registered laboratory infrastructure, kit fulfilment, specimen processing and clinical reporting. The companies are targeting execution of definitive agreements within approximately 30 days of signing the LOI, though no assurance has been given that a binding deal will be reached.
The deal
Kala Bio chief executive Avi Minkowitz framed the move as a commercial bridge alongside the company's longer-term pipeline ambitions. "Virotek's ophthalmology genetic testing program is exactly the kind of revenue-generating, accredited platform we believe belongs in Kala's commercial network," he said, adding that the company aims to "optimise KALA for growth" while developing its proprietary biologics programmes.
Virotek chairman and chief executive Saeid Babaei said Kala's commercial footprint in eye care gave the testing programme "a fast, credible path to patients across the U.S." Virotek, a Wyoming-based precision health and clinical genomics company, has built an integrated platform spanning preventive risk assessment, early cancer detection and personalised treatment guidance.
The companies have also sketched out a broader framework under which the collaboration could expand into oncology genetic testing, a preventive health franchise, and white-label telehealth channels, subject to mutual agreement.
Market context
Kala's interest in ophthalmic distribution is not a departure from its roots. The company, formerly Kala Pharmaceuticals, built and commercialised two FDA-approved ophthalmic therapies before divesting that commercial franchise to Alcon in 2022. Its clinical-stage pipeline is still centred on the eye, and it retains relationships across U.S. eye care. Adding a revenue-generating diagnostics stream through distribution rather than drug development carries a lower capital requirement, but it also means Kala depends on Virotek's platform performance and regulatory standing rather than its own.
The ophthalmology genetic testing market sits within a broader expansion of inherited disease diagnostics in eye care. Conditions such as retinitis pigmentosa and Leber congenital amaurosis have well-characterised genetic aetiologies, and genetic screening is increasingly integrated into clinical workflows ahead of gene therapy eligibility assessments. Several laboratory services groups and specialist diagnostics providers are active in this space, meaning Kala's success as a distributor will depend heavily on its salesforce effectiveness and the clinical credibility of Virotek's reporting platform.
It is also worth noting that Kala's corporate strategy has been in active flux. Its "About" section describes a pivot toward AI-driven infrastructure for the biotechnology sector, including a licensed agentic research platform called Researgency. The ophthalmology distribution deal adds a third strand to a strategy that already combines a biologics pipeline with an AI platform-as-a-service business. Investors may scrutinise whether the company has the operational bandwidth to pursue all three simultaneously, particularly given the disclosure in the forward-looking statements section of potential going concern risk and ongoing Nasdaq compliance challenges.
The LOI remains subject to corporate, regulatory and Nasdaq approvals. Near-term milestones to watch include the signing of definitive agreements, named eye care practice partners or telehealth platform clients, and any revenue guidance the company offers alongside its next quarterly filing.